Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin; Department of Breast Surgery, Guilin Women's and Children's Hospital, Guilin, China. .
Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Guilin Medical University, Guilin; Department of Breast Surgery, Guilin Women's and Children's Hospital, Guilin, China.
J Gastrointestin Liver Dis. 2024 Mar 30;33(1):94-101. doi: 10.15403/jgld-5289.
Systemic therapy is mainly recommended for advanced hepatocellular carcinoma (HCC). Considering the variety of treatments available for HCC, there is a need to understand their relative benefits and risks, especially for the newly approved combination of immune checkpoint inhibitors and vascular endothelial growth factor inhibitors represented by atezolizumab in combination with bevacizumab. A reticulated meta-analysis was used to evaluate the efficacy and safety of atezolizumab-bevacizumab combination therapy compared with other first-line systemic therapies for the treatment of patients advanced HCC.
PubMed, The Cochrane Library, Web of Science, and Embase databases were searched from the time of library construction to 01 December 2022, and the data were extracted and analyzed using Stata16.0 for Meta-analysis. The data were extracted separately, and a meta-analysis was performed using the software Stata16.0.
16 clinical studies with 8,779 subjects were identified from 13,417 records and were used to build the evidence network for all trials. TThe combination therapy of atezolizumab and bevacizumab has the advantage of prolonging the OS of patients when treating advanced HCC [HR=5.71, 95%CI (4.30, 7.12), p<0.05] Also, the combination therapy has the advantage of prolonging the patient's progression free survival [HR=1.60, 95%CI (0.89, 2.49), p<0.05].
Atezolizumab-bevacizumab combination therapy can improve clinical outcomes such as OS and PFS in patients with advanced HCC.
系统治疗主要推荐用于晚期肝细胞癌（HCC）。鉴于 HCC 有多种治疗方法，需要了解它们的相对益处和风险，特别是对于新批准的免疫检查点抑制剂和血管内皮生长因子抑制剂联合药物（以阿替利珠单抗联合贝伐珠单抗为例）。网状荟萃分析用于评估阿替利珠单抗-贝伐珠单抗联合治疗与其他一线系统治疗晚期 HCC 患者的疗效和安全性。
从建库时间到 2022 年 12 月 1 日，检索 PubMed、The Cochrane Library、Web of Science 和 Embase 数据库，并使用 Stata16.0 进行 Meta 分析提取和分析数据。分别提取数据，并使用软件 Stata16.0 进行 Meta 分析。
从 13417 条记录中确定了 16 项包含 8779 例患者的临床研究，并用于构建所有试验的证据网络。阿替利珠单抗联合贝伐珠单抗治疗晚期 HCC 时，具有延长患者 OS 的优势[HR=5.71，95%CI（4.30，7.12），p<0.05]。同时，该联合疗法还具有延长患者无进展生存期的优势[HR=1.60，95%CI（0.89，2.49），p<0.05]。
阿替利珠单抗-贝伐珠单抗联合治疗可改善晚期 HCC 患者的 OS 和 PFS 等临床结局。
Zotero 插件